Castle Creek Biosciences files plans for $100M IPO - Philadelphia Business Journal bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
Ysios Capital, a San Sebastian and Barcelona, Spain-based venture capital firm specialized in the biotechnology sector, closed its third fund, Ysios BioFund 3 (YBF 3), at €216m ($260m).
YBF 3 – Ysios’ largest fund to date – provides biotech ventures with the resources to develop novel and disruptive therapies for indications with high-unmet medical need. The fund will invest broadly across multiple therapeutic areas and modalities, targeting seed/early stage and development-stage companies at the forefront of the future of medicine.
The total investment size per company will typically be of up to €20m.
Led by Joël Jean-Mairet, Managing Partner, and Karen Wagner, Managing Partner, Ysios takes lead positions and works closely with entrepreneurial management teams. Emphasis will be placed on building sustainable companies with business models offering dual paths to liquidity. As with previous funds, about 80% of the YBF 3 investments will target Europe, with a special foc
Ysios BioFund 3 (YBF 3) is the firm's largest fund to date. To invest in up to 15 companies in Europe and the US, with eight investments already made alongside top US and European investors.
Pureos Bioventures Raises Additional USD35M; Fund Totals USD205M
The firm had
announced a USD170m close in September 2020. The supporters of the first Pureos fund include strategic partners, such as pharmaceutical and biotech companies as well as a large contract manufacturer, family offices, pension funds, fund-of-funds and other institutional investors.
Led by partners Klaus Breiner, Dominik Escher, Anja Harmeier, and Martin Münchbach, the firm will exclusively invest in innovative private drug development companies with an emphasis on novel biological drugs and emerging modalities such as nucleic acid, cell- and gene therapies. The fund’s portfolio companies are built on strong teams advancing therapies across a broad spectrum of indications including oncology, immunology, ophthalmology, rare diseases and neuroscience.
Gamma Delta T Cell Cancer Therapy Market To Transform Cancer Immunotherapy Landscape
USA - English
News provided by
Share this article Gamma Delta T Cell Cancer Therapy Opportunity & Clinical Trials Insight 2026
Report Highlights:
Insight on Key Drugs In Research & Development
Global Gamma Delta T Cell Cancer Therapy Clinical Trials Insight
Gamma Delta T Cell Cancer Therapy In Clinical Trials: > 15 Therapies
Gamma Delta T Cell Cancer Therapy Market Opportunity By Cancer Type
Adopted Approaches for Gamma Delta T Cell Therapy
Download Report:
In recent times, cancer immunotherapies have become an appealing strategy among various different therapeutic options and have demonstrated its power against wide range of malignancies. Advances in understanding of the dynamic interaction between the immune system and cancer have resulted in the development of a number of novel therapeutic strategies that harness several aspects of the immune system to treat cancer. Currently,